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Abstract 
In order to monitor the antibody response tofeline immunodeficiency virus (FIV) in cats, following 
experimental and natural infection, enzyme-linked immunosorbent assays (ELISAs) were developed 
using recombinant env and gag proteins and p24-specific monoclonal ntibodies. It was shown that 
in experimentally infected cats an env protein-specifc antibody response was directly followed by a 
gag protein-specific response. Furthermore, an ELISA for the detection of env protein-specific serum 
antibodies proved more sensitive inidentifying experimentally and naturally infected cats than ELISAs 
demonstrating gag protein-specific antibodies. Itwas concluded that, like in HIV infection of humans, 
the detection of env protein-specific serum antibodies in addition to gag protein-specific antibodies 
is not only an important tool in the diagnosis of the infection but also in studies concerning the 
pathogenesis of the disease. 
Introduction 
Feline immunodeficiency virus (FIV) is a T-lymphotropic lentivirus that was first isolated 
from domestic ats suffering from clinical signs indicative of an immunodeficiency syn- 
drome (Pedersen et al., 1987). The disease in cats is characterized by lymphadenopathy 
and severe impairment of immune function (Ackley et al., 1990; Siebelink et al., 1990a; 
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Torten et al., 1991 ) accompanied by a decrease of the number of CD4 T lymphocytes 
(Hoffmann-Fezet al., 1992). FIV has been shown to infect cat macrophages (Brunner 
and Pedersen, 1989), astrocytes (Dow et al., 1990) and the CD4 + sub set of T lymphocytes: 
a cell tropism similar to that of human immunodeficiency virus (HIV). Thus in many 
respects FIV infection in cats resembles HIV infection in man and therefore FIV infection 
should be considered a useful animal model for AIDS in man. The model has been shown 
suitable to study the potential of certain antiviral compounds (Egberink et al., 1990; Reming- 
ton et al., 1991), approaches for experimental vaccination (Yamamoto et al., 1991) and 
the pathogenesis of lentivirus induced immunodeficiency (Yamamoto et al., 1988). For 
these studies the development of assays to monitor the FIV-specific immune response after 
FIV infection and immunization with candidate vaccines is of critical importance. Several 
serological assays which demonstrate antibodies specific for the structural proteins of FIV 
have been described. These include enzyme-linked immunosorbant assays (ELISAs) based 
on whole virus preparations and immunofluorescence assays (IFA), both of which do not 
discriminate between antibodies directed against the individual FIV proteins (O'Connor et 
al., 1989; Siebelink et al., 1990b). Also Western blot and radio immunoprecipitation assays 
have been described (Lutz et al., 1988; Hosie and Jarrett, 1990; Egberink et al., 1992), 
which are, however, too laborious for routine serological procedures. Recently, virus neu- 
tralization assays have been developed, which demonstrate antibodies that may directly be 
involved in protection from infection or development of disease (Tozzini et al., 1992). 
With the advent of hybridoma, recombinant DNA and peptide synthesis technologies it 
has become possible to develop assay systems which can demonstrate antibodies directed 
to individual proteins or even individual epitopes. In the present paper we describe the 
comparison of four newly developed ELISAs based on the use of FIV-env and p24 recom- 
binant proteins and p24-specific monoclonal antibodies to monitor FIV-specific antibody 
development in the sera of naturally and experimentally infected cats. 
Materials and methods 
Virus preparat ions 
An FIV isolate (Adam 4) from a Dutch cat seronegative to FeLV and FeSFV, was 
obtained by cocultivating peripheral blood mononuclear cells (PBMC) with Concanavalin- 
A and Interleukin-2 stimulated PBMC from a specified pathogen-free (SPF) cat as previ- 
ously described (Siebelink et al., 1992). The FIV Petaluma strain was kindly provided by 
Dr. N.C. Pedersen (Davis, CA, USA). Crandell feline kidney (CrFK) cells (Crandell et 
al., 1973) were infected with FIV by cocultivation of CrFK cells with the infected PBMC 
as described ( Siebelink et al., 1990b) and cultured in Dulbecco' s minimal essential medium 
containing 100 IU/ml penicillin, 100/zg/ml streptomycin, 0.002 M glutamin and 5% fetal 
calf serum (FCS). Culture supernatants of the infected (and non-infected) CrFK cells were 
collected seven to ten days after passage of the cells in fresh medium. The culture super- 
natants were used as antigens in the CTB-ELISA (see below) after clarification by low 
speed centrifugation ( 10 min, 2000 rpm). 
For immunization purposes FIV was purified from culture supernatant bydensity gradient 
centrifugation. The virus was first pelleted by centrifugation for one hour at 100000 g at 
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4°C. The pellet was resuspended in phosphate buffered saline (PB S) and then layered over 
a discontinuous metrizamide (Nyegaard and Co, Oslo, Norway) gradient. After centrifu- 
gation for one hour at 100000 g at 4°C, virus containing fractions identified by a previously 
described ELISA (Siebelink et al., 1990b) were collected. 
Concentration a d partial purification of FIV antigen from culture supernatant was also 
performed by precipitation i polymer based aqueous two phase systems as described for 
other retroviruses (Hammar et al., 1989a; Hammar et al., 1989b; Hammar and Gilljam, 
1990). Polyethylene glycol 6000 (Merck, Schuckardt, Germany) and Dextran T 500 (Phar- 
macia, Uppsala, Sweden) were added to the culture supernatants at final concentrations of 
7% and 0.2% respectively. The mixture was allowed to equilibrate by gently rocking for 
16 hours at 4°C. Two phases were allowed to settle for another 16 hours at 4°C. Bottom and 
interphase (containing FIV) and top phase were collected separately. In this way a concen- 
tration of FIV of about 100-fold was achieved. This antigen was used for western blot assays 
(see below). 
Generation and selection of monoclonal antibodies (mAbs) 
A panel of hybridoma's producing mAbs in ELISA reactive with FIV, was generated 
essentially as previously described for the generation ofmAbs against poliovirus (Osterhaus 
et al., 1981 ). Briefly, spleen cells from BALB/c mice, which were subcutaneously immu- 
nized with 5 /xg gradient purified FIV in Freund's complete adjuvant on day 0 and in 
Freund's incomplete adjuvant on day 14, were fused with a mouse myeloma cell line after 
intraperitoneal booster injections on days 28, 29 and 30 with 5/zg of pelleted FIV. Hybrid- 
omas producing FIV-specific mAbs were selected by screening culture media in an ELISA. 
For this ELISA microtiter plates (Costar, High binding RIA/EIA plates) were treated by 
incubating 50/xl volumes of a PBS solution containing 0.125 mg poly-L-lysine and 10 mg 
1-ethyl-3 (3-dimethylaminopropyl)-carbodiimidehydrochloride (EDC) (Sigma, St. Louis, 
USA) per ml, for one hour at room temperature. After each incubation the plates were 
washed with demineralized water containing 0.05% Tween-80 (Merck, Schuckardt, Ger- 
many) (DWT). Fifty /xl volumes containing 300 ng of pelleted FIV or control antigen 
were coated in 0.1 M carbonate buffer, pH 9.6 for 16 hours at 20°C. The plates were blocked 
with 50 ~1 volumes of PBS containing 0.05% Tween-80 and 1% bovine serum albumin 
(BSA) (PBS-TB) for one hour at 37°C. Fifty/zl of undiluted culture supernatants were 
transfered to the wells and incubated for one hour at 37°C. After washing, 50/zl volumes 
of a horse radish peroxidase (HRP) conjugated goat anti-mouse IgG (Fc) antibody prep- 
aration (Cappel, Cooper Biomedical, Malvern, USA) were added to the wells and incubated 
for one hour. The plates were washed and 100/zl volumes of substrate solution (0.1 mg/ 
ml tetramethyl benzidin (TMB) and 0.003% H202 in 0.1 M NaAc buffer, pH 5.5) were 
added to each well. After incubation for 10 min at 20°C 100/zl volumes of 2 M H2SO4 
were added to stop the color reaction. The absorbance at450 nm (A450) was read in a 
Titertek Multiscan (Titertek, Flow Laboratories). Hybridomas were selected and single cell 
cloned twice by micromanipulation. Mouse ascitic fluids were produced in BALB/c mice. 
Immunoglobulins (Ig) were isolated from mouse ascitic fluids by precipitation with ammo- 
nium sulphate and affinity chromatography using protein A sepharose (Pharmacia Fine 
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Chemicals, Uppsala, Sweden) (Sepp~il~i etal., 1981). Ig classes and isotypes were deter- 
mined in an indirect ELISA with specific anti-Ig conjugates (Zymed Laboratories, CA, 
USA) and are indicated in brackets. 
Monoclonal antibodies were conjugated to biotin by incubating the antibody solution, 
which was dialyzed against 0.1 M NaCO3, pH 8.3 (1 mg protein per ml) with N-hydrox- 
ysuccinimido biotin (Sigma, St. Louis, USA) solubilized in dimethyl sulphoxide ( 1 mg/ 
ml ) at a 1:8 ( w /w ) ratio (biotin:protein) for four hours at room temperature. The conjugates 
were dialyzed against PBS and stored at - 20°C. 
SDS-PAGE and western blot analysis 
FIV (Adam 4) preparations were denatured in the presence of sodium dodecylsulphate 
and 2-mercaptoethanol and the individual viral proteins were separated on polyacrylamide 
gel (12%) by using the discontinuous buffer system (Laemli, 1970). Polypeptides were 
then electrically transfered to nitrocellulose sheets (Towbin et al., 1979). For immuno- 
staining the nitrocellulose was blocked with PBS-TB for one hour at 20°C and after each 
incubation washed three times for 10 min. 
After incubation with monoclonal antibodies or cat sera for one hour at 20°C, the nitro- 
cellulose was incubated with horse radish peroxidase (HRP) conjugated goat anti-mouse 
IgG (Fc) or goat anti-cat IgG (Cappel, Cooper Biomedical, Malvern, USA) respectively. 
Subsequently the nitrocellulose strips were developed with 24 mg tetramethyl benzidin and 
80 mg dioctyl sodium sulfosuccinate diluted in 10 ml ethanol supplemented with 30 ml 0.1 
M citrate/phosphate buffer pH 5.5 and 25/zl 30% H202. 
Recombinant FIV proteins 
Recombinant FIV enu protein, derived by PCR amplification of DNA from bone marrow 
cells of a naturally FIV-infected cat (cat Adam 19), was obtained by expression through 
recombinant vaccinia virus (rVV) vGR657 as described (Rimmelzwaan etal., 1993). In 
brief, HeLa spinner cells or BHK spinner cells were infected at a m.o.i, of five with rVV 
vGR657. After 48 hours, the cells were washed with PBS and lysed in PBS containing 0.5% 
NP-40 and 0.5% SDS. After centrifugation for 20 min at 10000 × g, the supernatant was 
used as FIV-env antigen in the respective assays. 
Recombinant FIV p24 and p17 protein were obtained by expression i  E. coli as fusion 
proteins using the pGEX-2T expression plasmid as previously described (Reid et al., 1991 ). 
Cats and serum samples 
Six female SPF cats of about 12 weeks old from a breeding colony (Harlan CPB, Zeist, 
The Netherlands), which is regularly screened for the absence of viral pathogens, were 
infected via the intravenous route with about 100 TCIDso of one of three different FIV 
strains. Two ( #5 and #6) with the Petaluma strain (kindly provided by Dr. N.C. Pedersen, 
Davis, CA, USA), two (#11 and #12) with a Dutch isolate (Adam 19) and two (#13 
and # 14) with the progeny virus of the infectious molecular clone 19KI that was obtained 
directly from bone marrow DNA of a naturally infected cat, from which also FIV isolate 
Adam 19 was obtained (Siebelink et al., 1992). Serum samples were collected at regular 
intervals after infection, while the animals were kept in strict isolation. 
Serum samples were also collected from 11 privately owned Dutch cats which were 
suspected of FIV infection on clinical grounds and positive serology in a commercial test 
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(Petcheck, IDEXX Corporation) and from 26 privately owned Dutch cats without clinical 
signs. 
ELISAs for the detection of  FIV-specific antibodies 
For the detection of FIV-specific antibodies, four indirect ELISAs were used. These 
ELISAs differed only in the antigen preparations u ed for the coating of the ELISA plates 
(Costar RIA/EIA, High binding). Optimal concentrations of the reagents used were deter- 
mined by checkerboard titration. The coating procedures ofthe four ELISAs were as follows: 
1. Total virus ELISA (TV-EL1SA). For the TV-ELISA, FIV antigen for coating was 
concentrated byultracentrifugation from supernatants of infected CrFK cell cultures. After 
solubilization with 1% w / v Triton X- 100 (Merck, Schuckardt, Germany), the antigen was 
diluted in 0.1 M NaAc buffer, pH 5.5, 50/xl volumes were added per well and the plates 
were incubated at room temperature for 16 hours. The wells were then emptied and fixed 
with 4% (w/v) paraformaldehyde for 10 min at room temperature. After washing the plates 
were blocked with PBS containing 0.05% Tween-80 and 10% FCS. 
2. ELISA based on FIV-specific mAbs ( MTV-ELISA ). For the MTV-ELISA microtiter 
plates were coated with purified mAb 8-21 (see below) in 0.1 M carbonate buffer, pH 9.6. 
The plates were washed with DWT containing 0.05% Tween-80 after each incubation. After 
blocking with PBS-TB for one hour at 37°C, 50/xl volumes of culture supernatants of FIV 
infected (or non-infected) CrFK cells, to which 1% Triton X- 100 and 5 % NaC1 was added, 
were incubated for one hour at 37°C. 
3. ELISA based on recombinant FIV-env protein ( rec.env-ELlSA ). For the rec.env- 
ELISA cell lysates of rVV vGR657 (or wild type vaccinia virus) infected RK13, BHK or 
HeLa cells were coated in 0.1 M NaAc buffer, pH 5.5 in 50/~1 volumes for 16 hours at 
room temperature. The wells were then emptied and fixed with 4% (w/v) paraformaldehyde 
for 10 min at room temperature. After washing the plates were blocked with PBS containing 
0.05% Tween-80 and 10% FCS. 
4. ELISA based on recombinant FIV p24/p 17 proteins (rec.gag-ELISA). The rec.gag- 
ELISA, based on recombinant gag proteins, was purchased from the European Veterinary 
Laboratory B.V., Woerden, The Netherlands (FIV-p24/p 17 antibody test kit, cat no. F 1002- 
AB01 ) and performed essentially as described previously (Reid et al., 1991 ). 
After coating and blocking of the microtiter plates, 50 ~1 of twofold serial dilutions of 
serum samples in PBS-TB supplemented with 5% NaC1 were added at a starting dilution 
of 1:40 or 1:20. Then the plates were incubated for one hour at 37°C. Subsequently 50 /zl 
volumes of a biotin conjugated mouse mAb directed to cat IgG (Sigma, St. Louis, USA) 
or an HRP conjugated goat anti-cat IgG antibody preparation (Cappel, Cooper Biomedicals, 
Malvern, USA) were added and the plates were incubated for one hour at 37°C. HRP bound 
streptavidin (Amersham, Amersham, UK) was allowed to bind to biotin for 30 min at 37°C. 
After each of these incubations the plates were washed with DWT and subsequently devel- 
oped with TMB as described above. 0D45o values were determined in a Titertek multiscan. 
Titres were given as the reciprocals of the dilutions still giving more than three times 
background values obtained with control antigen coated plates. 
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Complex trapping blocking ELISA (CTB-ELISA) for the detection of FIV p24-specific 
antibodies 
For the CTB-ELISA microtiter plates were coated with FIV p24-specific mAb 8-21 and 
blocked with PBS-TB as described for the MTV-ELISA. The plates were washed twice 
after each incubation with DWT. Twenty-five/zl volumes of twofold serial dilutions of cat 
serum samples, starting at a dilution of 1:5 were added simultaneously with 25 /xl of a 
dilution of culture supernatant of FIV infected CrFK cells giving 75% of maximum binding. 
All dilutions were prepared in PBS-TB supplemented with 1% Triton X- 100 and 5% NaC1. 
After incubation for two hours at 37°C, remaining binding of FIV antigen was detected 
using biotin conjugated mAb 2-13 (see below). The combination of mAb 8-21 as capture 
antibody and mAb 2-13 as conjugated antibody was chosen as it proved to be the most 
sensitive among those tested with the mAbs generated in these studies. After incubation 
with biotin conjugated mAb 2-13 for one hour at 37°C, HRP bound streptavidin was allowed 
to bind to biotin for 30 min at 37°C. The plates were developed as described above. Test 
samples were considered positive if a reduction of 50% or more of the signal was observed. 
Results 
Selection and characterization ofFIV-specific mAbs 
Five hybridomas, producing antibodies reactive with FIV antigen as determined in the 
hybridoma screening ELISA, were obtained from two fusion events. These mAbs were 
designated 2-11 ( IgGl,k) ,  2-13 (IgG2b,k), 3-20 (IgG2a,k), 4-22 ( IgGl,k) and 8-21 
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Fig. 1. Western blot analysis of FIV-specific mAbs. Viral proteins of two phase system purified FIV (lanes 1-7) 
or control antigen (lanes 8and 9) were separated bySDS-PAGE and electrically transferred to nitrocellulose. For 
immunostaining individual lanes were incubated with serum of a FIV seropositive cat (diluted 1: 100, lanes 1 and 
8), serum of a seronegative cat(diluted 1: 100, lane 2), culture supernatants of mAbs 2-11 (lane 3 ), 2-13 (lane 
4 and 9), 3-20 (lane 5), 4-22 (lane 6) and 8-21 (lane 7). 
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Fig. 2. Development of FIV-specific antibodies in experimentally infected cats. Antibody responses were moni- 
tored in the TV-ELISA (_ram_), MTV-ELISA (-E]-), rec.env-ELISA (-0-), rec.gag-ELISA (-A-) and CTB- 
ELISA (-©-) of: cats infected with the Dutch isolate Adam 19 of FIV (cats #11 and #12), cats infected with 
the progeny of infectious molecular clone 19K 1 (cats # 13 and # 14 ) and cats infected with the Petaluma strain 
of FIV (cats #5 and #6). 
( IgGl ,k) .  When tested for their reactivities in Western blot analysis, these five mAbs all 
reacted with the denatured p24 core protein of FIV (Fig. 1 ). No reactivity was found with 
control antigen concentrated and purified in the same way. The specificity of these five 
mAbs for the FIV gag protein was confirmed by demonstrating their reactivities in the 
rec.gag-ELISA (OD45o > 800 per 50 ng Ig) in which their respective isotype control mAbs 
did not react (data not shown). 
FIV-specific antibody responses in experimentally infected SPF cats 
The development of FIV-specific serum antibodies in experimentally infected cats was 
monitored in the respective ELISAs (Fig. 2). In two SPF cats (#11 and #12)  infected 
intravenously with the Dutch FIV isolate Adam 19 and two other S PF cats (# 13 and # 14) 
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Fig. 3. Comparison of  FIV-specific antibody levels in sera from naturally infected cats (n-11 ) obtained in the 
rec.env- and MTV-ELISAs,  the rec.em,- and rec.gag-EL1SAs, the rec.env- and CTB-ELISAs,  the rec.gag- and the 
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infected with the progeny of infectious molecular clone ( 19K 1 ), the development of serum 
antibodies to whole virus, FIV env and FIV gag proteins followed similar kinetics (Fig. 
2a). Immediately after the onset of env-specific response detected in the rec.env-ELISA 
which was found within three weeks post infection and led to titres > 5120 within five 
weeks, FIV gag protein-specific antibodies, measured in the rec.gag-ELISA and in the 
CTB-ELISA were detected. These increased rapidly during the subsequent weeks. In cat 
# 13 the antibody response to FIV gag protein seemed to develop slightly later. Antibodies 
measured in the TV- and MTV-ELISAs developed concomittently with the env-specific 
antibodies in these four cats. A relatively late development of FIV gag protein-specific 
serum antibodies was more pronounced in the two SPF cats (#5 and #6) infected intra- 
venously with the CrFK-cell adapted Petaluma strain of FIV (Fig. 2b). In cat #5 no FIV 
gag protein-specific antibodies could be detected within eight weeks post infection, whereas 
in cat #6 FIV gag protein-specific antibody titres slowly increased from five weeks post 
infection onward. These data coincided with the development of FIV gag protein-specific 
antibodies detectable in Western blot analysis in these two cats (data not shown). The 
development of env-specific serum antibodies did exhibit kinetics imilar to those observed 
in the other four cats. Serum antibodies measured in the TV- and MTV-ELISAs in cat #6 
were also similar to those of the other four cats, whereas the development of these antibodies 
in cat #5 again proved to be slower. 
FIV-specific antibodies in clinically healthy and clinically suspected cats 
Privately owned Dutch cats (n = 37) with (n = 11; positive in the TV-ELISA; Petcheck, 
IDEXX Corporation) and without (n = 26; negative in the TV-ELISA) clinical signs indic- 
ative for FIV infection, were tested for the presence of FIV-specific serum antibodies in the 
four newly developed ELISAs: MTV-, rec.env-, rec.gag-and CTB-ELISAs (Fig. 3). 
None of the serum samples from cats without clinical signs scored positive in any of the 
newly developed ELISAs. The 11 cats with clinical signs indicative for feline AIDS, all 
scored positive in the rec.env-ELISA, with titres ranging from 320 to >~ 5120. Of the 11 
positive samples three (samples A, B and C) scored consistently negative in the rec.gag- 
and the CTB-ELISA, and negative or low titred (titre= 20) in the MTV-ELISA. There 
proved to be an overall relation between the values found with the individual serum samples 
in the MTV-, rec.gag- and CTB-ELISAs which was not the case when the results of these 
assays were compared with those obtained in the more sensitive rec.env-ELISA. 
Discussion 
In this paper we have described four newly developed ELISAs based on different prin- 
ciples using recombinant FIV proteins or gag protein-specific monoclonal antibodies. New 
generations ofdiagnostic ELISAs are needed since the presently used classical assays, based 
on whole virus preparations have been shown to score too many false positives (Siebelink 
et al., 1990b; Reid et al., 1991 ). Furthermore, ELISAs based on this principle do not allow 
the identification of antibodies directed against individual viral proteins, which as in the 
case of HIV infection of humans may be of major importance for studies concerning the 
pathogenesis of the disease (Lange et al., 1986a; Allain et al., 1986; Allain et al., 1987; 
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Weber et al., 1987). All except he CTB-ELISA were based on the use of antigen coated 
plates to quantitate FIV gag- or env-specific antibodies in feline sera. With sera from 
experimentally infected cats it was shown that, as in HIV-1 infections in man (Saah et al., 
1987; Race et al., 1991), env-specific antibodies were detected before the appearance of
gag-specific antibodies. This difference was most pronounced in cats infected intravenously 
with the CrFK adapted Petaluma strain of FIV. The overall slower development of FIV- 
specific antibodies in these two cats as compared to those infected with the Dutch isolate 
Adam 19 or the molecular clone 19K1 indicates that either strain differences or adaptation 
of the virus to CrFK cells may directly influence the initial replication rate of the virus. The 
relatively slow development of gag-specific antibodies inthe cats infected with the Petaluma 
strain was confirmed by showing that these findings coincided well with the development 
of antibodies reactive with p24 in the Western blot assay (not shown). After having 
monitored the development of serum antibodies, detectable with these assays in the exper- 
imentally infected cats during the first months after infection, their value for the detection 
of naturally infected omestic ats was studied by testing the serum samples of 11 cats 
suspected of suffering from FIV infection on basis of clinical signs and subsequent positive 
serology in the Petcheck ELISA. All the 26 clinically healthy cats scored negative when 
tested in all the newly developed serological tests. Among the 11 TV-ELISA positive cats, 
all scored positive in the rec.env-ELISA. Of these, three (samples A, B and C) were negative 
or borderline positive in the ELISAs detecting antibodies directed to the FIV gag protein. 
From cats A and C PBMC could be obtained, from which FIV was isolated (data not 
shown). This indicates that results found in the rec.env-ELISA are indeed confirmatory for 
FIV infection and that the other three ELISAs may fail to identify some FIV infected cats. 
Although the envelope glycoprotein s subject o antigenic variation which may result in 
lack of reactivity with serum antibodies of cats infected with heterologous virus, no evidence 
was provided with the serum samples tested that his was the case. However, the combination 
of serological ssays detecting both FIV env- and gag-specific antibodies, circumvents his 
possible problem and should be considered confirmative for FIV infection. 
For the detection of gag-specific antibodies, the use of the MTV-ELISA based on FIV 
gag-specific monoclonal antibodies may be less suitable since agglomerates of different 
virus proteins may be bound to the plates. The results obtained with sera from experimentally 
infected (#5 and #6) cats suggest that this is indeed the case (Fig. 2). 
A discrepancy in the presence of env- vs. gag-specific antibodies, as was shown in the 
early stages of infection in the experimentally infected cats #5 and #6, may cause false 
negative serological results when a system is used that does not detect env-specific antibod- 
ies. Such discrepant results may perhaps also be expected when cats progress towards AIDS, 
as has been documented in HIV symptomatic nfections in man, in which gag-specific 
antibodies, either due to immune complex formation or loss of functional B lymphocytes, 
decline while env-specific antibodies persist (Lange et al., 1986a,b; 1987; Weber et al., 
1987; McHugh et al., 1988; Teeuwsen et al., 1991). The discrepancies found in FIV gag- 
vs. env-specific antibodies in cats A, B and C may be a reflection of this phenomenon since 
they all exhibited serious igns of immunodeficiency at the time of sampling. Since a small 
number of animals has been tested, these ELISA systems hould be used to test more cats 
in different stages of disease to assess that these phenomenons indeed play a role in FIV 
G.F. Rimmelzwaan etal. / Veterinary Microbiology 39 (1994) 153-165 163 
pathogenesis. The documented failure of serological assays to identify "silently" FIV 
infected cats (Hopper et al., 1989), may perhaps be attributed to their inability to detect 
FIV env  protein-specific antibodies. A similar observation has been described for certain 
HIV infections which initially were believed not to induce serum antibodies (Saah et al., 
1987; Race et al., 1991 ). 
In conclusion the data presented indicate that ELISAs based on the simultaneous detection 
of FIV env  and gag protein-specific serum antibodies are highly specific and sensitive tools 
for the serology of FIV infection in cats. They also allow detailed studies of mechanisms 
underlying certain kinetics of the FIV-specific antibody response that have been documented 
also in HIV infections of humans. 
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